Evidence map›Paper›PMID 42685700›Full record

ArticleCell reports. Medicine2026

Preferential engagement of the anti-inflammatory ATP/adenosine axis by HIV vaccine candidate with V1-deleted envelope in male rhesus macaques.

Isabela Silva de Castro, Mohammad Arif Rahman, Massimiliano Bissa, Katherine C Goldfarbmuren, Luca Schifanella, Sarkis Sarkis, Kombo F N'guessan, Zhong-Min Ma, Anna Gutowska, James D Stamos and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Isabela Silva de CastroAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mohammad Arif RahmanAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Massimiliano BissaAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Katherine C GoldfarbmurenAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA; Center for Cancer Research Collaborative Bioinformatics Resource, National Cancer Institute, Bethesda, MD, USA.
Luca SchifanellaAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sarkis SarkisAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kombo F N'guessanHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; U.S. Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Zhong-Min MaCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Anna GutowskaAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James D StamosAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Melvin N DosterAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Emmanuel K WoodeAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Justin C SmithDepartment of Microbiology, Immunology & Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Pamela A KozlowskiDepartment of Microbiology, Immunology & Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
LaTonya D WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA; Division of Surgical Sciences, Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
Katherine M McKinnonOffice of Science and Technology Resources Flow Cytometry Core, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA; Division of Surgical Sciences, Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA; Division of Surgical Sciences, Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA; Division of Surgical Sciences, Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
Sampa SantraBoston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Dominic Paquin-ProulxHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA; U.S. Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Frank MaldarelliHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Timothy CardozoNew York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA.
Genoveffa FranchiniAnimal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: franchig@mail.nih.gov.

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
NIAID NIH HHS HHSN272201100016CNIAID NIH HHS P30 AI064518
6 · The paper itself

Abstract

We evaluate the efficacy and immunogenicity of HIV clade A/E A244 envelope (Env) immunogens with the 23 amino acids of variable region 1 deleted (ΔV1) or retained (wild-type [WT]) in macaques. Only the ΔV1 regimen significantly reduces the risk of mucosal acquisition of clade C simian/human immunodeficiency virus (SHIV)

Indexed as

AIDS VaccinesAnti-Inflammatory AgentsHIV Envelope Protein gp120AnimalsAntibody-Dependent Cell CytotoxicityCD4-Positive T-LymphocytesHIV-1HumansMacaca mulattaMaleSimian Immunodeficiency VirusAIDS VaccinesAnti-Inflammatory AgentsHIV Envelope Protein gp120ATP/Adenosine axisconformational V2-epitopedecreased mucosal CD4(+) T cell activationefferocytosismucosal CD73(+) cellsmucosal epithelial fortificationmucosal immunityprotective effect of monocyte subsetsV1-Env deleted HIV vaccineV2-directed ADCC

Identifiers

PMID42685700
PMCPMC13589499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.